利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.013 秒)

    Sustained analgesia achieved with buprenorphine
    2.
    发明公开
    Sustained analgesia achieved with buprenorphine 失效
    用丁丙诺啡持续镇痛

    公开(公告)号：EP2301494A1

    公开(公告)日：2011-03-30

    申请号：EP10185241.6

    申请日：1998-02-24

    申请人： EURO-CELTIQUE S.A.

    发明人： Reder, Robert, F. ,  Goldenheim, Paul, D. ,  Kaiko, Robert, F.

    IPC分类号： A61F13/00 ,  A61K31/485 ,  A61K9/70 ,  A61P25/04

    CPC分类号： A61K31/485 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/7023 ,  A61K9/7053 ,  A61K9/7061 ,  A61K31/4748

    摘要： A transdermal delivery device containing buprenorphine for treating human patients suffering from opioid addiction by applying onto the skin of the patient and maintaining the transdermal delivery device in contact with the skin for a 3 day dosing interval, the transdermal delivery device containing an amount of buprenorphine sufficient to maintain an adequate relative release rate to provide a plasma concentration of from about 1000 pg/ml to about 10,000 pg/ml at the end of said 3 day dosing interval, and the transdermal delivery device being maintained in contact with the skin of the patient for at least 2 to about 5 additional days beyond said 3 day dosing interval, such that the patient continues to receive effective treatment for opioid addiction from said transdermal buprenorphine delivery device over said dosing interval.

    摘要翻译： 一种含有丁丙诺啡的透皮给药装置，用于治疗患有阿片样物质成瘾的人类患者，所述装置通过施用到患者的皮肤上并保持透皮给药装置与皮肤接触3天的给药间隔，该经皮给药装置含有足够量的丁丙诺啡 以维持足够的相对释放速率以在所述3天给药间隔结束时提供约1000pg / ml至约10,000pg / ml的血浆浓度，并且透皮递送装置与患者的皮肤保持接触 在所述3天给药间隔之后至少2至约5天，使得患者在所述给药间隔内继续接受来自所述透皮性丁丙诺啡递送装置的阿片样物质成瘾的有效治疗。

    Substained analgesia achieved with buprenorphine
    3.
    发明公开
    Substained analgesia achieved with buprenorphine 失效
    透皮贴剂具有为丁丙诺啡在治疗疼痛的用途为至少4天的给药间隔

    公开(公告)号：EP1570823A2

    公开(公告)日：2005-09-07

    申请号：EP05011213.5

    申请日：1998-02-24

    申请人： Euro-Celtique S.A.

    发明人： Reder, Robert, F. ,  Goldenheim, Paul, D. ,  Kaiko, Robert, F.

    IPC分类号： A61F13/00 ,  A61K31/485 ,  A61K9/70 ,  A61P25/04

    CPC分类号： A61K31/485 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/7023 ,  A61K9/7053 ,  A61K9/7061 ,  A61K31/4748

    摘要： The use of buprenorphine in the preparation of a medicament for a method of effectively treating pain in humans is achieved by administering buprenorphine in a manner indicative of first order pharmacokinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in a manner indicative of zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.

    摘要翻译： 在制备用于治疗的有效治疗人类疼痛的方法使用丁丙诺啡的是通过在指示第一顺序的药代动力学在初始3天的给药间隔的方式管理丁丙诺啡实现，检查了来自约20做了最大血浆浓度 微克/毫升到约1052微克/毫升达到，并且此后保持丁丙诺啡的给药以指示零级动力学的方式至少在两个额外的天给药间隔，检查没有患者经历镇痛遍及所述至少两 天额外给药间隔。

    Substained analgesia achieved with buprenorphine
    8.
    发明公开
    Substained analgesia achieved with buprenorphine 失效
    Analgetisch wirksame Zusammensetzung mitverzögerterWirkstoffabgabe von Buprenorphin

    公开(公告)号：EP1570823A3

    公开(公告)日：2006-01-18

    申请号：EP05011213.5

    申请日：1998-02-24

    申请人： Euro-Celtique S.A.

    发明人： Reder, Robert, F. ,  Goldenheim, Paul, D. ,  Kaiko, Robert, F.

    IPC分类号： A61F13/00 ,  A61K31/485 ,  A61K9/70 ,  A61P25/04

    CPC分类号： A61K31/485 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/7023 ,  A61K9/7053 ,  A61K9/7061 ,  A61K31/4748

    摘要： The use of buprenorphine in the preparation of a medicament for a method of effectively treating pain in humans is achieved by administering buprenorphine in a manner indicative of first order pharmacokinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in a manner indicative of zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.

    摘要翻译： 丁丙诺啡的持续释放配方是新的。 组合物包含透皮递送装置，其在3天给药间隔内提供丁丙诺啡的一级释放，使得获得20×10 10 2 pg / ml的最大血浆浓度。 该装置然后在至少2天以上提供零级动力学。